PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Neuro and cognitive

Semax

Also written as: ACTH(4-7)-Pro-Gly-Pro, ACTH(4-7)PGP, MEHFPGP, Met-Glu-His-Phe-Pro-Gly-Pro

Semax is a seven-amino-acid peptide built from a fragment of the hormone ACTH and registered as a nasal medicine in Russia; its human evidence comes from small, mostly uncontrolled Russian studies, and the FDA judged it insufficient.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • Semax is a synthetic seven-amino-acid peptide built from part of the hormone ACTH. It was developed in Russia, where it is registered as a medicine in nasal-drop form. It is not FDA-approved, and no EMA approval was found.
  • In rats it raised BDNF, a protein that supports nerve cells, and reduced brain damage in stroke models.
  • The human studies come almost entirely from Russia, are small, are mostly in Russian, and often had no placebo group. The FDA judged the evidence insufficient for stroke, migraine or facial nerve pain, and no semax trials are listed on ClinicalTrials.gov.
  • Safety has barely been studied. The FDA found no standard animal toxicity studies and no human data on how the body handles semax, and flagged rodent findings on blood clotting and dopamine.
  • FDA staff proposed in May 2026 not allowing pharmacies to compound it. An October 2026 HHS draft, non-binding policy names semax and covers only the free base used into the nose, under conditions.
  • Semax is not named on the anti-doping Prohibited List. Because it is approved in Russia, it is unclear whether the catch-all class S0 applies.

What it is

Semax is a peptide, a short chain of amino acids, the building blocks of proteins. It is seven amino acids long: Met-Glu-His-Phe-Pro-Gly-Pro. The first four match positions 4 to 7 of ACTH (adrenocorticotropic hormone), a pituitary hormone. Three more amino acids (Pro-Gly-Pro) are added at the end; researchers think they make the peptide harder for enzymes to break down.

More on what it is and where it came from

Despite its origin, semax is reported to lack ACTH's hormonal effects. The FDA's review describes it as 'devoid of the hormonal corticotropic and melanotropic properties' of ACTH, meaning it does not drive the adrenal glands to make stress hormones or affect skin pigment.

In Russia it is a registered medicine, given as nasal drops. In the United States and Europe it is not an approved medicine. It is sold online as a 'nootropic' (a supposed memory and focus enhancer), and the FDA notes products are sold under the same name in different chemical forms.

Semax was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, led by Igor Ashmarin and Nikolai Myasoedov, building on work showing that small fragments of ACTH affect learning in animals. A 1997 paper by the developers described about 15 years of work on it, placing its origins in the early 1980s. It was then registered as a medicine in Russia; the year was not confirmed from a primary source.

How it is thought to work

In rat studies, semax raised levels of BDNF and nerve growth factor, natural proteins that help nerve cells survive and form connections, in brain areas involved in memory. In rat stroke models it changed the activity of many genes, mostly those linked to the immune system and to blood-vessel growth. These are hypotheses from animal work; how semax switches genes on or off is unknown.

More on how it works

It belongs to the melanocortin family, peptides related to ACTH, but no study testing semax at specific melanocortin receptors was found. Radio-labelled semax bound to a specific, unidentified site in rat brain tissue. In rodents it also raised serotonin activity and strengthened amphetamine's effect on dopamine. In rats it reduced blood clotting, possibly through Pro-Gly-Pro, the main fragment left after it breaks down.

It is broken down quickly in rat blood. In rats, more of it reached the brain when given into the nose than into a vein, though still only a tiny fraction of the amount given. No studies in people show how it is absorbed or cleared.

What is established in people

Very little is established in people by international standards. The human studies of stroke, reduced brain blood flow, optic nerve disease and motor neuron disease come from Russia, are small, are mostly in Russian-language journals, and often had no placebo group or did not describe how patients were assigned; many came from groups linked to semax's development. The FDA excluded the Russian stroke studies for lack of English translations, and judged the two studies it could assess too weak to show benefit. No independent trials outside Russia and no trials on ClinicalTrials.gov were found. The one study in motor neuron disease found no effect on the disease.

What the studies found

12 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2018

    The efficacy of semax in the tretament of patients at different stages of ischemic stroke

    Patients given semax had higher BDNF in the blood throughout the study, whatever the timing of rehabilitation.

    Full finding, who was studied, and limits

    Who: 110 adults in stroke rehabilitation in Moscow (43 men, 67 women, mean age 58), split into early rehabilitation (about 3 months after the stroke) and late rehabilitation (about 7 months), each divided into patients who did and did not receive semax. Followed for 5 months.

    Patients given semax had higher BDNF in the blood throughout the study, whatever the timing of rehabilitation. The authors reported that semax and higher BDNF were linked to faster and better recovery of daily-living ability (Barthel index) and, to a lesser degree, to recovery of muscle strength. Early rehabilitation also helped.

    Read with care: The abstract does not give the size of each subgroup, how patients were chosen for semax, or any placebo or blinding. A blood BDNF level is an indirect marker, not a proven measure of recovery. The FDA did not evaluate it because no English translation was available.

    Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (Russian-language journal) · pubmed.ncbi.nlm.nih.gov

  2. Human trial2018

    Effects of Semax on the Default Mode Network of the Brain

    Brain scans at rest (functional MRI) showed changes in a network of brain areas active during rest in the semax group compared with the placebo group.

    Full finding, who was studied, and limits

    Who: 24 healthy volunteers (11 men, 13 women, mean age about 44): 14 given semax into the nose and 10 given a placebo. Brain scans before and 5 and 20 minutes after.

    Brain scans at rest (functional MRI) showed changes in a network of brain areas active during rest in the semax group compared with the placebo group.

    Read with care: Very small, a single dose, and it measured brain-scan patterns, not memory, attention or any health outcome. The abstract does not say whether volunteers were randomly assigned or blinded. A 2020 paper from the same team may have used the same volunteers.

    Bulletin of Experimental Biology and Medicine · pubmed.ncbi.nlm.nih.gov

  3. Human trial2007

    The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax

    Semax did not change the course of nerve damage measured by muscle tests, or the clinical rating scales of the disease.

    Full finding, who was studied, and limits

    Who: 27 patients with motor neuron disease (which includes ALS) given semax into the nose in an open-label study (everyone knew they were getting semax). Russia.

    Semax did not change the course of nerve damage measured by muscle tests, or the clinical rating scales of the disease. The authors reported better quality-of-life scores, mainly mood and motivation, peaking at day 10.

    Read with care: Small, no comparison group and no blinding, so the quality-of-life change may not be due to semax. It is included because it is a negative result on the disease itself.

    Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (Russian-language journal) · pubmed.ncbi.nlm.nih.gov

  4. Human trial2005

    Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency

    The authors reported clinical improvement, slower progression, and a lower risk of stroke and mini-strokes, and described side effects as few and the drug as well tolerated, including in older patients.

    Full finding, who was studied, and limits

    Who: 187 patients with long-term reduced blood flow to the brain (cerebrovascular insufficiency) at different stages. Russia.

    The authors reported clinical improvement, slower progression, and a lower risk of stroke and mini-strokes, and described side effects as few and the drug as well tolerated, including in older patients.

    Read with care: The abstract gives no comparison group, no numbers for the outcomes and no information on how patients were assigned, so the claims cannot be checked from what is available.

    Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (Russian-language journal) · pubmed.ncbi.nlm.nih.gov

  5. Human trial2000

    Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease

    The authors reported better and faster recovery in the semax groups, with improvements in sharpness of vision, field of vision, colour vision and electrical tests of the optic nerve.

    Full finding, who was studied, and limits

    Who: Patients with several kinds of optic nerve disease, including partial optic nerve atrophy, in three groups: semax nasal drops, semax delivered through the nose by a mild electric current, and a control group. All received standard treatment. The abstract does not give numbers.

    The authors reported better and faster recovery in the semax groups, with improvements in sharpness of vision, field of vision, colour vision and electrical tests of the optic nerve.

    Read with care: Patient numbers, blinding and allocation are not stated in the abstract. A 2001 study in glaucoma patients from another Moscow group also reported benefit but its abstract gives no numbers.

    Vestnik Oftalmologii (Russian-language journal) · pubmed.ncbi.nlm.nih.gov

  6. Human trial1997

    Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)

    The authors reported that adding semax had 'some influence' on how quickly lost functions recovered, especially movement, judged by clinical rating scales, brain-wave recordings and nerve-response tests.

    Full finding, who was studied, and limits

    Who: 30 patients in the first days after a stroke, given semax on top of standard care, compared with 80 patients with similar strokes on standard care alone. Moscow, Russia.

    The authors reported that adding semax had 'some influence' on how quickly lost functions recovered, especially movement, judged by clinical rating scales, brain-wave recordings and nerve-response tests.

    Read with care: Small, with an unequal comparison group. The abstract does not describe random allocation, blinding or a placebo. It was run by the group linked to semax's development. The FDA did not evaluate it because no English translation was available.

    Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (Russian-language journal) · pubmed.ncbi.nlm.nih.gov

  7. Review2026

    FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Semax-related bulk drug substances (semax (free base) and semax acetate)

    Counting the studies it could assess, the FDA found semax had been given into the nose to 33 to 47 healthy adults, 69 adults with medical conditions and 451 children (the children only in conference abstracts).

    Full finding, who was studied, and limits

    Who: The FDA's own review of the published chemistry, animal and human evidence on semax, written for its advisory committee.

    Counting the studies it could assess, the FDA found semax had been given into the nose to 33 to 47 healthy adults, 69 adults with medical conditions and 451 children (the children only in conference abstracts). It found no data for injection under the skin and no human studies of how the body handles semax. It excluded the Russian stroke studies because no English translations were available. In one study it could assess (Koroleva 1996), headache stopped in 4 of 12 migraine patients and semax did not relieve typical trigeminal neuralgia (a facial nerve pain); there was no control group. It concluded the evidence was insufficient for stroke, migraine or trigeminal neuralgia, and proposed not adding either form of semax to the list of substances pharmacies may compound from.

    Read with care: A regulator's review, not a new study. It deliberately left out Russian-language papers without translations, so it does not weigh most of the stroke research.

    U.S. Food and Drug Administration; evaluation memo dated 11 May 2026 · fda.gov

  8. Animal study2014

    The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis

    Across the whole genome, semax mainly changed the activity of genes linked to the immune system (over half of the genes it affected) and to blood-vessel growth.

    Full finding, who was studied, and limits

    Who: Rats with a permanent blockage of a main brain artery (a stroke model), with and without semax, examined at 3 and 24 hours. The abstract does not give the number of animals.

    Across the whole genome, semax mainly changed the activity of genes linked to the immune system (over half of the genes it affected) and to blood-vessel growth. The authors proposed that effects on the immune response and blood vessels may underlie its protective effect in stroke models.

    Read with care: Gene activity in rat brain tissue, not recovery. The authors called the mechanism of semax 'obscure' before this study, and it remains a hypothesis.

    BMC Genomics · pubmed.ncbi.nlm.nih.gov

  9. Animal study2007

    Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10

    Within an hour, activity of the genes for two nerve-support proteins (BDNF and nerve growth factor) rose in the hippocampus.

    Full finding, who was studied, and limits

    Who: Healthy male Wistar rats given semax into the nose once and examined one hour later. The abstract does not give the number of animals.

    Within an hour, activity of the genes for two nerve-support proteins (BDNF and nerve growth factor) rose in the hippocampus. BDNF gene activity also rose in the brainstem and cerebellum, while nerve growth factor gene activity fell in the frontal cortex. The authors described rapid changes that differed by gene and brain region.

    Read with care: Gene activity measured in rat brain tissue, not a health outcome. The FDA notes that how semax changes gene activity is unknown.

    Neuroscience Letters · pubmed.ncbi.nlm.nih.gov

  10. Animal study2006

    Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus

    In the hippocampus, a brain area involved in memory, levels of BDNF protein rose by up to 1.4-fold and activation of its receptor (trkB) by 1.6-fold.

    Full finding, who was studied, and limits

    Who: Rats given a single dose of semax into the nose. The abstract does not give the number of animals.

    In the hippocampus, a brain area involved in memory, levels of BDNF protein rose by up to 1.4-fold and activation of its receptor (trkB) by 1.6-fold. BDNF (brain-derived neurotrophic factor) is a natural protein that helps nerve cells survive and form connections. Treated rats also performed more avoidance responses in a learning task. The authors suggested this BDNF effect may explain semax's reported effects on learning.

    Read with care: Rats, one dose, from the group that developed semax. A rise in a brain protein in rats does not show any benefit to thinking or memory in people.

    Brain Research · pubmed.ncbi.nlm.nih.gov

  11. Animal study2006

    Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex

    The damaged brain area was smaller in semax-treated rats; the FDA's review describes it as about 20% smaller than in rats given water.

    Full finding, who was studied, and limits

    Who: Rats with a small, light-induced stroke in the front of the brain, treated into the nose for six days and compared with untreated and sham-operated rats. Group sizes are not given in the abstract.

    The damaged brain area was smaller in semax-treated rats; the FDA's review describes it as about 20% smaller than in rats given water. Treated rats also kept a learned avoidance response that untreated stroke rats lost.

    Read with care: Rats, one research group, a single dose level. The FDA notes that these stroke studies did not test different doses or measure how much semax reached the blood.

    Bulletin of Experimental Biology and Medicine · pubmed.ncbi.nlm.nih.gov

  12. Animal study2005

    Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents

    Semax raised a breakdown product of serotonin (a brain chemical messenger) in the striatum, a deep brain region, by up to 180% over a few hours.

    Full finding, who was studied, and limits

    Who: Mice (the FDA review identifies them as male C57BL/6 mice) given semax by injection into the abdomen.

    Semax raised a breakdown product of serotonin (a brain chemical messenger) in the striatum, a deep brain region, by up to 180% over a few hours. On its own it did not change dopamine. Given before amphetamine, it strongly increased amphetamine's effect on dopamine release and on movement.

    Read with care: Mice. The FDA's 2026 review called the amphetamine finding concerning because raised dopamine in the striatum is typical of drugs of abuse, and noted that no study has tested whether semax is habit-forming.

    Neurochemical Research · pubmed.ncbi.nlm.nih.gov

Safety findings

  • Most published human studies did not report on side effects at all. In the 1996 study of 37 adults with migraine or facial pain, the authors reported none. The FDA concluded there is not enough clinical information to describe semax's safety. Source: fda.gov
  • The 2005 Russian study of 187 patients with reduced brain blood flow described side effects as few and the drug as well tolerated, but the abstract gives no figures. Source: pubmed.ncbi.nlm.nih.gov
  • No human pharmacokinetic studies (how the body absorbs and clears it) exist for any route, and there are no safety data at all for injection under the skin. Published human use is only into the nose. Source: fda.gov
  • The FDA found no acute toxicity, repeat-dose toxicity, genotoxicity (damage to genes), or pregnancy and development studies in animals. The one cancer-related mouse study was not designed to assess cancer risk. Source: fda.gov
5 more safety findings
  • In rats, semax reduced blood clotting and made clots smaller. The FDA said this raises a possible bleeding risk, especially for people prone to bleeding or taking other drugs that affect clotting. This has not been studied in people. Source: fda.gov
  • In mice, semax boosted amphetamine's effect on dopamine in a way the FDA compared with drugs of abuse. Whether semax is habit-forming has not been tested. Source: pubmed.ncbi.nlm.nih.gov
  • The FDA's side-effect database held one report up to December 2025: a consumer who used semax nasal drops bought online reported eye pain and burning, was hospitalised, and still had eye pain a year later. One report cannot show cause. Source: fda.gov
  • The FDA said compounded semax may risk unwanted immune reactions for some routes because of possible clumping (aggregation) and impurities, and that it 'lacks sufficient information to know whether the drug would cause harm if administered to humans'. Source: fda.gov
  • HHS read the same record differently: its October 2026 draft policy says the nasal human record covers 'several hundred subjects with no reported adverse outcome' and that the bleeding and abuse signals have no clinical counterpart. As the FDA noted, most of those studies did not report side effects either way. Source: hhs.gov

Rules and status

Not approved. Semax is not an FDA-approved medicine, is not part of any approved drug, and has no US Pharmacopeia standard. It is registered as a medicine in Russia, as nasal drops.

The full history, with dates

Russia: the FDA's 2026 review states that semax is a registered drug in Russia, sold as nasal drops, citing Russia's State Register of Medicines (not opened by the researcher; the site is in Russian). It also appeared on Russia's list of vital and essential medicines for 2020, approved by Government Order No. 2406-r of 12 October 2019: Annex 1 lists it under its chemical name (methionyl-glutamyl-histidyl-phenylalanyl-prolyl-glycyl-proline), in the group 'other psychostimulants and nootropic drugs' (code N06BX), as nasal drops. That was read from a ConsultantPlus copy of the order posted on a Russian regional health service website, not from the government's own portal, and later yearly versions of the list were not checked, so its place on the list in 2026 is not confirmed. No EMA approval was found. United States: the FDA placed semax in Category 2 (substances that may present significant safety risks) on 29 September 2023. The nominators withdrew, and the FDA page current as of 22 April 2026 lists it under 'nominated but withdrawn', with the reason that compounded semax 'may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.' It is in no category on the FDA list updated 14 May 2026. The FDA reviewed it anyway: its briefing document (memo dated 11 May 2026) proposed not adding semax free base or semax acetate to the list pharmacies may compound from. HHS states that the advisory committee, meeting on 23 and 24 July 2026, voted in favour of both forms; FDA's own minutes were not found. On 30 October 2026 HHS published notice (91 FR 68526) of a draft, interim, non-binding policy under which it does not intend to take enforcement action against licensed pharmacies or physicians compounding certain peptides. Semax is one of the six peptides in its Appendix A. Appendix B limits this to semax free base (sequence H-Met-Glu-His-Phe-Pro-Gly-Pro-OH) for use into the nose, made from ingredient with a certificate of analysis that meets the policy. HHS gave three reasons: newer certificates from FDA-registered sources supply the endotoxin result the FDA had called the main gap, plus identity, purity, impurity, solvent and salt-form data; historical use is now documented; and the FDA's safety concerns are 'mechanistic rather than observed'. General conditions include a patient-specific prescription, a single active ingredient, an FDA-registered original manufacturer, reporting of serious side effects and quality problems to FDA MedWatch, and the label statement 'This is a compounded drug product. Not for resale.' This is enforcement discretion, not approval. The comment period closed in mid-November 2026, and no final version was found.

Source: hhs.gov (source dated 2026-10-30)

In sport: Semax is not named on the World Anti-Doping Agency's Prohibited List for 2026 or 2027 (full text checked). Whether it is prohibited is not settled by the documents. Class S0 prohibits at all times any substance not covered elsewhere on the List 'with no current approval by any governmental regulatory health authority for human therapeutic use'. Semax is registered as a medicine in Russia, so on the List's own wording S0 may not apply to it. WADA's 2027 note says that many peptides 'not approved for human use by regulatory authorities' fall under S0 and that an unnamed peptide may still be prohibited, but it does not mention semax or say how approval in one country is treated. Separately, class S2.2.2 prohibits corticotrophins (ACTH and related substances), and S2 covers 'other substances with similar chemical structure or similar biological effect(s)'. Semax is built from part of ACTH but is reported to lack ACTH's hormonal action, and no WADA document addresses whether S2 applies. No WADA statement on semax was found. WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
Semax raises BDNF and so builds a better brain.In rats, semax raised BDNF in memory-related brain areas. One Russian stroke-rehabilitation study found higher blood BDNF in patients given semax, but the abstract gives no placebo or blinding. No study shows that raising BDNF this way improves thinking in healthy people. Source: pubmed.ncbi.nlm.nih.gov
It is a proven nootropic (memory and focus enhancer) for healthy people.The healthy-volunteer studies are tiny. The most recent, in 24 people, measured brain-scan patterns after one dose, not memory or focus. The FDA found no professional guideline or adequate study supporting a 'nootropic' use. Source: pubmed.ncbi.nlm.nih.gov
It is an approved stroke drug, so it is proven to work.It is registered in Russia, but the stroke studies are small, Russian-language and mostly without placebo control. The FDA could not assess them, stroke guidelines do not mention semax, and ClinicalTrials.gov lists no semax trials. Source: fda.gov
It has no side effects.Most studies did not report on side effects. There are no standard animal toxicity studies and no human data on how the body handles it. Rodent studies raised possible bleeding and abuse-potential concerns that have not been tested in people. Source: fda.gov
The FDA legalised semax in 2026.FDA staff recommended against allowing it in compounding. HHS's October 2026 policy is a draft, non-binding statement that it does not intend to take enforcement action against compounding of semax free base for use into the nose, under conditions. It is not an approval. Source: govinfo.gov
It helps ALS and other nerve-wasting diseases.In the one study found, 27 patients with motor neuron disease, semax did not change the course of the disease. Only mood-related quality-of-life scores improved, without a comparison group. Source: pubmed.ncbi.nlm.nih.gov

What a genuine lab report should show

  • Identity by mass spectrometry: the measured mass should match the seven-amino-acid sequence Met-Glu-His-Phe-Pro-Gly-Pro, 813.9 g/mol for the free base. The FDA gives 874.0 g/mol for the acetate salt.
  • Which form it is: free base or acetate salt. The FDA treats them as different substances, and the HHS draft policy covers only the free base.
  • The name should match the substance tested. The FDA found different salts and derivatives sold under the name 'semax', and found nominators' certificates that named one form in the title and gave the formula of the other.
  • Purity by HPLC, with peptide-related impurities listed rather than a single percentage alone.
  • Tests for bacterial toxins (endotoxin) and microbial contamination. The FDA called the missing endotoxin result the main gap in the certificates it reviewed.
  • A lot number and test date that match the product, and a named laboratory.

How to read a lab report

What is not known

  • How the 2018 stroke-rehabilitation study was designed: subgroup sizes, how patients were chosen for semax, and whether anyone was blinded. Only the abstract could be read.
  • Whether semax falls under WADA class S0. It is registered in Russia, and S0 covers only substances with no current approval by any government health regulator. Whether class S2 (corticotrophins and substances like them) could apply is also unaddressed. No WADA ruling was found.
  • Whether semax is still on Russia's vital and essential medicines list in 2026. The list was read from a reproduction of the 2019 order for 2020, not from the government portal or a later version.
  • Russia's State Register entry was not opened (Russian-language site); its registration is reported here from the FDA briefing document. The year of first registration was not confirmed.
  • How semax acts. Rat studies point to BDNF, immune and blood-vessel genes, and serotonin and dopamine. A specific binding site was found in rat brain, but no receptor has been identified, and no study testing semax at melanocortin receptors was found.
  • How many distinct people have received semax in published studies. The FDA's count includes 451 children described only in conference abstracts, and two healthy-volunteer papers may share subjects.
  • HHS says the nasal human record shows no reported adverse outcome, while the FDA notes that most of the same studies did not report on side effects. Both readings come from the same small record.
  • The HHS draft policy limits any co-packaged delivery device to a 510(k)-cleared syringe, while covering semax only for use into the nose. How that applies to a nasal product is unclear.
  • The advisory committee's July 2026 vote is reported here from HHS's appendix. FDA minutes were not found.
  • Whether the HHS draft policy has been finalised. The comment period closed in mid-November 2026 and no later notice was found.

Sources

All 25 sources
  1. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus (2006). pubmed.ncbi.nlm.nih.gov
  2. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10 (2007). pubmed.ncbi.nlm.nih.gov
  3. Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex (2006). pubmed.ncbi.nlm.nih.gov
  4. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis (2014). pubmed.ncbi.nlm.nih.gov
  5. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents (2005). pubmed.ncbi.nlm.nih.gov
  6. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study) (1997). pubmed.ncbi.nlm.nih.gov
  7. The efficacy of semax in the tretament of patients at different stages of ischemic stroke (2018). pubmed.ncbi.nlm.nih.gov
  8. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency (2005). pubmed.ncbi.nlm.nih.gov
  9. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease (2000). pubmed.ncbi.nlm.nih.gov
  10. Effects of Semax on the Default Mode Network of the Brain (2018). pubmed.ncbi.nlm.nih.gov
  11. The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax (2007). pubmed.ncbi.nlm.nih.gov
  12. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Semax-related bulk drug substances (semax (free base) and semax acetate) (2026). fda.gov
  13. FDA: bulk drug substances that may present significant safety risks (page current as of 22 April 2026). fda.gov
  14. FDA: 503A nominated substances by category, updated 14 May 2026. fda.gov
  15. HHS: 503A peptide enforcement-discretion policy, Appendices A and B (read from an Internet Archive capture of 15 November 2026). hhs.gov
  16. Federal Register, 30 October 2026, 91 FR 68526: HHS draft enforcement-discretion policy notice. govinfo.gov
  17. Russian Government Order No. 2406-r of 12 October 2019, list of vital and essential medicines for 2020 (ConsultantPlus copy on a regional health service site). med-b-izmalkovskaya-r42.gosweb.gosuslugi.ru
  18. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study) (1997). pubmed.ncbi.nlm.nih.gov
  19. Development of Peptide Biopharmaceuticals in Russia (2022). pmc.ncbi.nlm.nih.gov
  20. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats (2024). pubmed.ncbi.nlm.nih.gov
  21. ClinicalTrials.gov search for 'semax' (no registered studies, checked 18 November 2026). clinicaltrials.gov
  22. WADA: 2026 Prohibited List. wada-ama.org
  23. WADA: 2027 Prohibited List. wada-ama.org
  24. WADA: 2027 Prohibited List, summary of major modifications and explanatory notes. wada-ama.org
  25. PubChem: Semax, CID 9811102. pubchem.ncbi.nlm.nih.gov

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sent to your email, with a note when a compound page or its legal status changes.

Sign-up link not connected yet.